|Articles|June 8, 2022

Tissue IHC: Translating Technology into Patient Testing After Biomarker Target is ID

Author(s)Frontage Laboratories, Inc.

In the discovery and investigation of novel biomarkers, tissue immunohistochemistry (IHC) studies are critical, but how do you translate the technology into the clinical laboratory for patient testing once a biomarker target has been identified?

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Articles

Leveraging remote-based regional hubs in FSP partnerships
June 26th 2025
Establishing a Bespoke Outsourcing Arrangement with Hybrid FSP/FSO Partnerships
June 26th 2025
2025 FSP Trends Report
June 26th 2025
Focus on biotech: Harnessing FSP engagements to deliver on-time, on-budget
June 19th 2025
FSP Outsourcing in Clinical Research: Trends and Opportunities
June 9th 2025
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025

Trending on Applied Clinical Trials Online

Latest NIMBLE Study Results Highlight Progress in gMG Research

Trial Data Leads to NCCN Recommendation for Modeyso in Recurrent High Grade Glioma Patients

Q&A: Strategies for Successful Global Clinical Trial Delivery

Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients

© 2025 MJH Life Sciences^®

All rights reserved.